Antidiabetic preparation for oral administration

Details Antidiabetic preparation for oral administration Antidiabetic preparation for oral administration

2006-04-04

2006-04-04

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S464000, C424S465000, C424S469000, C424S472000, C424S474000, C424S480000, C424S484000

Reexamination Certificate

active

07022339

ABSTRACT:
There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.

REFERENCES:
patent: 5296236 (1994-03-01), Santus et al.
patent: 6143323 (2000-11-01), Yabuki et al.
patent: 6559188 (2003-05-01), Gatlin et al.
patent: 6638535 (2003-10-01), Lemmens et al.
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2003/0124191 (2003-07-01), Besse et al.
patent: 0 793 959 (1997-09-01), None
patent: 0 864 325 (1998-09-01), None
patent: 0 965 339 (1999-12-01), None
patent: 10-231242 (1998-09-01), None
patent: 11-139960 (1999-05-01), None
patent: 2001-2583 (2001-01-01), None
patent: WO 94/05277 (1994-03-01), None
patent: WO 98/02105 (1998-01-01), None
patent: 98/56378 (1998-12-01), None
patent: WO 00/40233 (2000-07-01), None
patent: 01/21159 (2001-03-01), None
patent: WO 01/47557 (2001-07-01), None
patent: WO 01/475577 (2001-07-01), None
Mekalex Medicine Name “Starlix/Natelinide”; http://mekalex.com/MKX—med/mekamed—detail.cfm?medicine—id.
Japanese Patent Laid-Open Publication No. Hei 11-130696, Publication Date May 18, 1999.
Journal of Clinical and Experimental Medicine, Jan. 30, 1999, vol. 188, No. 5, pp. 518-521.
Starlix, , Novartis Package Insert, DJN 608/Nateglinide, Jan. 4, 2001, pp. 1-12.
Doctors Guide Global Edition, FDA Approves Starlix (Nateglinide) for Type Diabetes, Dec. 27, 2000, pp. 1-3.
Web address: http//www.home.eznet.net/˜webtent/repaglinide.html, Repaglinide (Prandin), printed on Jun. 24, 2002.
Carol Lewis, Diabetes: A Growing Public Health Concern, U.S. Food and Drug Administration, FDA Consumer Magazine, Jan.-Feb. 2002.
U.S. Food and Drug Administration, FDA Consumer Magazine, Oral Antidiabetes Medications, Jan.-Feb. 2002.
U.S. Food and Drug Administration, FDA Consumer Magazine, Oral Antidiabetes Medications, Jan.-Feb. 2002. http://fdagov.google.com/fdagove?client+fdagove5q . . . eatures%wF2002%2Fchrt—oralmeds@2Ehtml+melformin.

Affiliated with

Also associated with

Rating

Antidiabetic preparation for oral administration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antidiabetic preparation for oral administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidiabetic preparation for oral administration will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3605592